A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings
DeciBio delivered an in-person presentation to a client team, with the results of the analysis synthesized for understanding current patterns and future trends in RNA-based oncology biomarkers
DeciBio delivered Excel databases of findings and analyses of:
5 weeks
U.S.
Clinical Diagnostics
Voice-Of-Customer Research
Competitive Analysis
Biomarker and Diagnostic Strategy
Customer Segmentation